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Multiple myeloma is the second most common hematologic cancer. It is characterized by the clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood or urine, and associated organ dysfunction. 1 Multiple Myeloma usually occurs between 40 and 70 years of age. 2 Multiple myeloma occurs slightly more frequently in men than in women (1.6:1). 3, 4 Nearly 74,800 Americans currently have MM, and an estimated 10,700 will die from the disease in 2012. 5 Multiple Myeloma accompanied by nonspecific symptoms such as generalized fatigue, weight loss, and bone pain on movement. Osteolytic lesions and pathological fractures may be seen on skeletal survey. 2 Multiple Myeloma can cause many complications, including Calcium elevation (hypercalcemia), Renal (kidney) dysfunction, Anemia and Bone disease. This constellation of signs and symptoms is commonly referred to as "CRAB". 5 Multiple Myeloma can present as pathology in practically all the orbital and ocular tissues. Early identification and early treatment is necessary to prevent irreversible visual loss. Ophthalmic manifestation in multiple myeloma is rare. Retinal vascular disorders have been reported in up to 66% of patients with multiple myeloma. Retinal features of hyper viscosity include venous dilatation, segmentation and tortuosity, superficial and deep hemorrhages and detachment of both the sensory retina and retinal pigment epithelium. 6 The two pathophysiological processes that give rise to a majority of the ophthalmic signs are tissue infiltration by plasma cells and hematological abnormalities. 2 Laboratory tests characteristically reveal a normocytic normochromic anemia, raised erythrocyte sedimentation rate, hypercalcemia, renal dysfunction, Bence Jones proteinuria and monoclonal globulin spike on serum electrophoresis. Bone marrow biopsy usually confirms the diagnosis by showing an uncontrolled proliferation of plasma cells. 2, 7, 8 There is no one standard treatment for MM, and choice of therapy depends on many factors, including physical exam and laboratory test results, the specific stage or classification of the disease, age and general health, symptoms, presence of complications and prior treatment. Commonly used regimens for initial therapy include traditional agents such as corticosteroids (e.g., dexamethasone) and alkylating agents such as melphalan.
5
METHOD
This is about a case report. A man 45-year-old, complained loss of vision on both eyes especially left eye over 1 month. He also feels weakness and 2 times spontaneous nose bleeding. His visual acquity is 6/12 on the right and 2/60 left eye. Anterior Segment examination in normal limit. Dilated Fundus examination showed dilatation and tortuosity vein (sausage shape) with dot, blot, flame shape, roth spot and decrease macular reflex on the right eye. We found vitreous hemorrhage with dilatation and tortuosity vein (sausage shape), subhyaloid bleeding and decrease macular reflex on the left eye. Ocular Computed Tomography was done and showed increase in Central Retinal Thickness (CRT) 317µm on the right eye and 482 µm on the left. We consulted this patient to Internal department but unfortunately the patient came to emergency room with spontaneous nose bleeding on the next day. His Laboratory result increase in WBC 65.91x10 3 /µL (Neutrophil, Monocyte, Basophil and Lymphocyte) decrease RBC 3x10 6 /µL, HGB 6.85g/dL, normal PLT 193.60x10 3 /µm. The patient was consulted to Hemato Oncology and was planned to bone marrow aspiration with diagnosed suspect Acute Myeloid Leukemia.
Picture 2. OCT Macula show increase Central Retinal
Thickness (Courtesy by VR Division), RE =Right eye, LE= Left Eye
Patient was consulted to our division. On our examination we found visual acquity is 6/12 on the right and 5/60 left eye. Anterior Segment examination in normal limit. Dilated Fundus examination showed dilatation and tortuosity vein (sausage shape) with dot, blot, flame shape, roth spot and decrease macular reflex on the right eye. We found decrease on vitreous hemorrhage with dilatation and tortuosity vein (sausage shape), subhyaloid bleeding and decrease macular reflex on the left eye. We planned to observation and waited for the bone marrow aspiration resulted.
Bone marrow aspiration was done 3 days after the patient was consulted to our division. The resulted are Multiple Myeloma with Hipercelluler, Erytroid Sytem Activity, Myeloid Sytem Activity, Megakaryocites Sytem Activity decrease and 40 % Plasma Cell Infiltration. Electrophoresis and bone survey was planned. We found increased in Gamma Globulin 8.62 g/dL (0.9-1.5), 71.8% (12.1-21.1) with total protein 12 g/dl. Bone Survey examination showed didapatkan Lytic soliter lesion on left frontal bone. Multiple Myeloma Stage IIIA was diagnosed by hemato-oncology division and the patient was given Melphalan 6 mg two times per day and prednisone 20 mg three time per day for 5 days and repeated for 28 days. 
RESULT
After 10 cycles of melphalan therapy, patient came to eye policlinic. On our examination we found visual acquity is 6/6 on the right eye and 6/10 with pinhole not improve on the left. Dilated funduscopy examination we found complete resolution on the right eye with no bleeding and tortuosity. Macular reflex are positive. On the left eye we found weiss ring and fibrosis in the vitreous, with no subhyaloid bleeding, but unfortunately the macular reflex still decreased. 
DISCUSSION
Multiple myeloma is a hematologic malignancy caused by infiltration of bone marrow by bone marrow-derived plasma cells followed by the production of monoclonal Ig by these cells. Symptomatic hyperviscosity is observed in 2%-6% of patients with multiple myeloma.
9,10 Multiple myeloma is characterized by bone pain, skeletal punched out lesions, anemia, renal insufficiency, hypercalcemia, and increased susceptibility to infections. Ocular involvement with multiple myeloma can be found throughout the eye and visual pathways as well as the orbit, although rarely are these the presenting signs. Specifically, the retina may have dilated and tortous veins, retinal hemorrhages, Roth spots, vitreous hemorrhages, cotton wool spots and exudates, and central and branch retinal vein occlusions. Uncommonly, retinal and choroidal detachments can be seen in multiple myeloma. 9, 11, 12 This case is unusual in that the initial presentation of the patient was significant decrease in visual acuity 6/12 on the right and 2/60 left eye. Posterior examination we found with roth spot and intraretinal bleeding with venous dilatation and turtuosity. Macula reflex decrease on the right and hazy (bleeding) on vitreous with subhyaloid bleeding, intraretinal bleeding, venous dilatation and turtuosity . Macula reflex decrease. OCT macula show CRT on RE 317µm and LE 482 µm.
Retinal bleeding is caused by hyperviscosity syndrome of Multiple myeloma. The shear wall stress due to increased blood viscosity is greatest on vessels with the smallest cross-sectional area and highest flow rates, providing an explanation for localization of haemorrhage to the arteriolar beds. Retinal vein swelling and haemorrhage is probably secondary to compression of the central optic vein due to retinal artery engorgement as a result of increased viscosity. 13 Exudative retinal detachment that happen in this case is unusual. Dogan et al speculate that Ig accumulation in the subretinal space increases the oncotic pressure, while fluid accumulation in the subretinal area separates the RPE from the photoreceptors. Multiple Myeloma is classified as asymptomatic or symptomatic, depending on the absence or presence related organ damage. 1 Laboratory tests characteristically reveal a normocytic normochromic anemia, raised ESR, hypercalcemia, renal dysfunction, Bence Jones proteinuria and monoclonal globulin spike on serum electrophoresis . Bone marrow biopsy confirms the diagnosis (uncontrolled proliferation of plasma cells).
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Our patient was diagnosed Multiple Myeloma Stage IIIA by hemato-oncology division and the patient was given Melphalan 6 mg two times per day and prednisone 20 mg three time per day for 5 days and repeated for 28 days.
Since the 1960s, melphalan and steroid have been the standard of therapy. Chemotherapy consisted of oral melphalan (8 mg/m) on days1-4 and oral dexamethasone (40 mg/day) on days 1-4 and days 9-12. The cycles were repeated every 28 days for a total of 12 cycles or until intolerance or disease progression was observed. 13, 14 This case of bilateral retinal bleeding and exudative retinal detachment are remarkable for both its presentation and response to therapy. Our case is also remarkable in that there was a favorable response to therapy by way of visual acuity improvement, resolution on retinal bleeding and exudative retinal detachment after 10 cycles therapy with melphalan and prednisone although there is PVD complete and fibrosis after vitreous hemorrhage on the left eye.
CONCLUSION
Complication of Multiple Myeloma can caused organ disfunction such as retinal bleeding and exudative retinal detachment. Early Diagnosis is very crucial. In our case combination cemotheraphy with Melphalan and Prednison showed clinically significant resolution. Workship Internal Department and Ophthalmology Department are very important for management and monitoring ophthalmology manifestation in multiple myeloma.
